Form 4 for MNPR Monopar Therapeutics
Accepted 2022-01-04 00:00:00 ET · period of report 2022-01-01 · accession 0001654954-22-000130 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-04 | 2022-01-01 | MNPR | Mazar Andrew Paul | CSO, Dir | F - Tax | $3.21 | -671 | 21.0K | -3% | -$2,154 |
| D | 2022-01-04 | 2022-01-01 | MNPR | Mazar Andrew Paul | CSO, Dir | M - OptEx | — | +1,937 | 21.7K | +10% | — |
| D | 2022-01-04 | 2022-01-01 | MNPR | Mazar Andrew Paul | CSO, Dir | M - OptEx | $0.00 | -1,937 | 3,874 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-01 | F | D | 671 | $3.21 | 20,989.80 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-01 | M | A | 1,937 | — | 21,660.80 | D | — | — | (F1) Represents shares acquired on vesting and settlement of restricted stock units. |
| 3 | Derivative | Restricted Stock Units | 2022-01-01 | M | D | 1,937 | $0.00 | 3,874 | D | — · — to — | 1,937 Common Stock | (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 31, 2020 the reporting person was granted 7,748 restricted stock units, vesting in four equal annual installments with vesting dates on January 1, 2021, January 1, 2022, January 1, 2023, and January 1, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. |